Podcasts about google play spotify

Alan & Rob chat to DC Exclusive Artist Cian Tormey, the man who brought Superman to Dublin, Ireland in Superman: Son of Kal-El! Cian brings us through his secret origin story - through all the trials and tribulations that led him to leave a successful career in advertising so that he could chase his dreams as a comic book artist, finally landing an exclusive contract with DC, with some of his top tips for budding professionals.  PLUS! We chat Superman: Son of Kal-El and the amazing whirlwind response to the history-making book including how the book has so positively impacted members of the LGBTQI community.  If you've ever day dreamed of leaving your career behind and following your dreams into the world of creating comic books, don't miss this episode! RATE AND REVIEW THE SHOW ON APPLE PODCASTS, PODBEAN, GOOGLE PLAY & SPOTIFY, PLEASE AND THANK YOU! FACEBOOK:  @allstarsuperfan INSTAGRAM: @allstarsuperfan TWITTER:  @allstarsuperpod EMAIL:  allstarsuperpod@gmail.com Thanks to Shawn Allen for our music & Aaron Price for our logo. Social media poster designed by Rob O'Connor with original pencils by Cian Tormey, colours by Federico Blee and letters by Dave Sharpe.

In this JCO Precision Oncology Conversations podcast, JCO PO author Dr. Thanh Dellinger of City of Hope National Medical Center shares insights into the research published in her article, “Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.” Podcast host Dr. Abdul Rafeh Naqash talks with Dr. Dellinger about hyperthermic intraperitoneal chemotherapy (HIPEC) and the various challenges of the treatment of epithelial ovarian cancer (EOC). The study described in this JCO PO article discusses protein expression, RNAseq alterations and signature, and whole-transcriptome sequencing and signatures. Read here  https://ascopubs.org/doi/full/10.1200/PO.21.00239   TRANSCRIPT Dr. Abdul Rafeh Naqash: Welcome to ASCO's Precision Oncology Conversations where we bring you the highlights and overview of precision oncology. This podcast is here to provide interactive dialogue focusing on the excellent research published in the JCO Precision Oncology. Our episodes will feature engaging conversations regarding precision oncology with the authors of a clinically relevant and highly significant JCO Precision Oncology article. You can find all our shows including this one at asco.org/podcasts, or wherever you get your podcasts. Hello, I am Dr. Abdul Rafeh Naqash. I'm a medical oncologist and a phase one clinical trialist at the OU Stephenson Cancer Center. You're listening to JCO Precision Oncology Conversations. I have no conflicts of interest related to this podcast. A complete list of disclosures is available at the end of each episode. Today, I will be talking with Dr. Thanh Dellinger from the City of Hope Comprehensive Cancer Center, who's a gynecological oncologist, and we'll be talking about her JCO Precision Oncology article, ‘Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.' Dr. Dellinger does not have any conflicts of interest. Hi, Dr. Dellinger, welcome to our podcast! Dr. Thanh Dellinger: Hi, Dr. Naqash! It's such a pleasure to be on with you. Dr. Abdul Rafeh Naqash: We recently saw your paper published. It's one of those interesting, clinical translational papers that we felt needed to be highlighted in our Precision Oncology Podcast series. So, we're really excited to have you here today to take a deeper dive into the findings and some of the novel approaches that you used in your recent publication. So, for starters, could you give our listeners a brief idea of what HIPEC is, where it's used, and when it's used in ovarian cancer? Dr. Thanh Dellinger: Right! Thank you very much for this great introduction. So, HIPEC or Hyperthermic Intraperitoneal Chemotherapy has been used in ovarian cancer for quite some time. The most relevant data giving us an indication for ovarian cancer was published by Dr. van Driel in the OVHIPEC-1 randomized trial several years ago in the New England Journal of Medicine, which demonstrated that in stage 3 ovarian cancer patients who undergo an interval tumor debulking with HIPEC, that those patients appear to enjoy both progression-free and overall survival benefit. In fact, the overall survival benefit is nearly 12 months for those patients. So, with this in mind and a number of other data, the HIPEC treatment for those patients that interval debulking has been incorporated into the NCCN guidelines. Nonetheless, there have been some criticisms of HIPEC and it still remains to be seen who those patients are, the ovarian cancer patients who really best benefit from HIPEC, given the morbidity of HIPEC. We now know also that HIPEC is probably equivalent to just cytoreductive surgery alone in terms of morbidity. Dr. Abdul Rafeh Naqash: Thank you for that explanation. And especially for people like myself, who are not surgeons or gynecological oncologists, that was very helpful. So, my next question, and you probably partly answered it, but I'm going to still ask the question is: what is the reason you think that intraperitoneal chemotherapy overall, has not been as widely adopted? Dr. Thanh Dellinger: You touch on a very good point there. As many of the listeners may understand, IP chemotherapy has demonstrated a lot of efficacies in multiple clinical trials over the last decade or two decades even. And part of why, despite its benefit, it has not been taken up in the overall community may really be the difficulty and the complexity of doing IP chemotherapy in the community, especially the side effects are difficult sometimes to take care of. There's increased abdominal pain and there are catheter issues. And so, especially with more recent data, that with the presence of Avastin, IP chemotherapy may not necessarily be as beneficial. Unfortunately, IP chemotherapy hasn't been really taken up in daily oncologic care with ovarian cancer. Nonetheless, we know that there are a lot of theoretical benefits because of the peritoneal metastasis not being as best treated with intravenous chemotherapy as with regional therapy. Dr. Abdul Rafeh Naqash: Thank you! So, now going to the data that you published. I was very intrigued with some of the findings. And from what I understood, your main aim was to understand predictive biomarkers to identify patients or basically identify molecular characteristics for patients' selection for HIPEC. So, could you tell us more about why you initiated this study? And I understand this is one of the, I believe the first study in humans to evaluate some of these interesting biomarkers, both pre- and post-. So, what was the background of doing this trial? And what led to this interesting study? Dr. Thanh Dellinger: Thank you for pointing out this aim. There's a lot of criticism of HIPEC and part of it is that we may not exactly understand the mechanisms of HIPEC, why is it that it works so well in some patients? There's a lot of preclinical data supporting hyperthermia, especially with cisplatin. There's synergy between cisplatin and hyperthermia, and improving the DNA adduct formation. There's increased cytotoxicity seen when the temperature increases up to 43 degrees. And there's also a T-cell activation and immune response that occurs during hyperthermia. So, a lot of this, however, has been done in preclinical studies, in vitro data as well as preclinical mouse models. There hasn't been much or really anything published that, as far as I know, has been done in humans. And so, this particular study looked at both pre-treatments, pre-HIPEC specimens, peritoneal biopsies, as well as immediate post-operative peritoneal biopsies, tumors, and normal samples, and we wanted to look both at the whole transcriptomic sequencing profile, but also at the tumor microenvironment. Dr. Abdul Rafeh Naqash: From a logistic standpoint, from a trial design standpoint, was this a phase 1 study? I know you use the term pilot in the publication. So, were you trying to look at safety also, or was this primarily I would say, a biomarker, pharmacodynamic biomarker-driven study that you were trying to evaluate? Dr. Thanh Dellinger: You're correct. This was essentially a feasibility study. But we additionally looked at safety and feasibility with HIPEC at our institution. And in some respects, we also looked at the feasibility of giving intraperitoneal chemotherapy normothermically early after HIPEC, and so it was also an endpoint to look at safety. Dr. Abdul Rafeh Naqash: Understand! I believe there was some difference in the dose for the cisplatin, I believe, is the chemotherapy that you use. What was the rationale for the difference in the dose for 75 milligrams per meter square that you use in your study? Dr. Thanh Dellinger: The study was initiated at a time before the OVHIPEC-1 trial was published. And so, at that time, the HIPEC dose for cisplatin was still not established. 75 milligrams per meter square for cisplatin was actually used in other trials, and has been noted to be effective in other clinical trials. Dr. Abdul Rafeh Naqash: Thank you! Now going to the patient population for this trial. What type of patients were you enrolling? Was it just epithelial ovarian cancer patients, did these patients need to have peritoneal metastases when you were doing this cytoreductive surgery? What was the patient population that you were targeting in this trial? Dr. Thanh Dellinger: The majority of the patients did have epithelial ovarian cancer. We did enroll a few, actually 5, uterine cancer patients as well, which were not included in this specific publication. But the majority of them were epithelial ovarian cancer patients. Dr. Abdul Rafeh Naqash: Going to the interesting translational analysis. So, you had three subsets of patients based on the biopsy collection. What were your hypotheses, and what drove some of those translational studies to understand the biomarkers? Dr. Thanh Dellinger: The first translational analysis we conducted was the whole transcriptomic sequencing, and specifically, we wanted to look, one, for any potential transcriptomic signatures that may correlate with survival or improved response to HIPEC. The second one was to look at whole exome sequencing. Thirdly, we looked at whole transcriptomic sequencing differences before and after HIPEC treatment. And lastly, we looked at the tumor microenvironment through multiplexing of certain markers associated with T-cell response. Dr. Abdul Rafeh Naqash: From a clinical outcome standpoint - and we'll discuss the biomarkers in more detail - from a clinical standpoint, when I briefly looked over the PFS curves, were the results, as far as expected outcomes, were they similar to what you see with the current standard? Or were there any unusual safety signals? Or would you attribute any of the adverse events that you saw to intraperitoneal chemotherapy specifically? Because I believe some patients did have some chemotherapy pre-surgery, neoadjuvant if I'm correct. So, how would you attribute some of those AEs, and if at all, did you see any interesting safety signals of concern and outcomes as far as PFS is concerned? Dr. Thanh Dellinger: So, one of the major toxicities that we saw in the first half of our trial were actually renal toxicities. In fact, there were actually two patients who could not go on to adjuvant chemotherapy because they suffered chronic renal failure. And because of that, halfway through the trial, we did actually add a nephro protectant called sodium thiosulfate. And this actually dramatically improved those renal toxicities. And for the second half of our study, no patients suffered grade three or grade four renal adverse events. And so, that did change significantly. Dr. Abdul Rafeh Naqash: From a genomic standpoint, it's very interesting that you were able to do all these very cool and interesting translational biomarker studies, including multiplex immunofluorescence. From a genomic standpoint, though, would you say it's fair to say that there was no significant correlation based on the baseline genomics for some of the patients and their outcomes? Is that a fair assessment? Dr. Thanh Dellinger: Yes, that is a very fair assessment. I think that our cohort was really too small to make those kinds of assessments. I don't know whether you saw there recently was a paper published by the OVHIPEC-1 group looking at their cohort of over 200 patients that underwent the interval cytoreductive surgery in HIPEC and they did actually demonstrate benefit in patients who are HIV-positive but BRCA wild-type, but not necessarily in BRCA mutated patients. So, I think that I would point to that study to look for genomic effects with HIPEC patients. Dr. Abdul Rafeh Naqash: Understand. Now, again, going to the biomarkers that your team evaluated, it seems from among good responders especially, you saw an increase in tumor necrosis factor, alpha signaling, NF-kappa B signaling, KRAS signaling, and then you also saw some pathways that were downregulated, especially the G2-M checkpoint, and Myc targets. What would you say the correlation of these is in terms of future drug development in this specific setting? Dr. Thanh Dellinger: I think that we did see some increase in immune pathways in patients who did better in the end. And also, our multiplex results did demonstrate that E1 expression was increased in patients who had better responses after HIPEC. So, our hypothesis is that potentially, there's an activation of T-cell response with HIPEC and that potentially PD-1 inhibitor could be added in the future. This is a hypothesis that certainly would need to have more work, but it's something that is interesting enough to really look at in ways of how to improve HIPEC. Dr. Abdul Rafeh Naqash: Going to your point on the PD-1, I found really intriguing that you were able to see an increase in PD-1 expression on CD8+ T cells but no actual increase in the number of CD8+ T cells suggesting there's some sort of activation of this marker and this may not necessarily be a marker for T-cell exhaustion. So, would you interpret it in a way that in a different setting, perhaps a new adjuvant approach with immunotherapy, would perhaps somehow augment this and then you could see more upregulation? Is there any work being done in that field? How would you put this in the context of your findings? Dr. Thanh Dellinger: You bring up a really great point because to date HIPEC has been demonstrated to have benefit in the interval setting. But there was a more recent study done by, well not recent, a more recently published study by a Korean group that demonstrated no benefit in the adjuvant setting for HIPEC and still some benefit in the interval setting. And the question is, are these really two different types of cohorts who respond differently because of potential differences in immune response and tumor microenvironment? I think that that would be a great way of delving further into this. What are really the differences in tumor microenvironment changes in those two different settings? Dr. Abdul Rafeh Naqash: Definitely! It's very exciting. You've also shown upregulation of, as you mentioned earlier, immune pathways, as well as upregulation of genes related to heat shock proteins. Does that play into future drug development as far as HSP Inhibitors are concerned? Dr. Thanh Dellinger: That is a really great question. Certainly, in preclinical models, heat shock proteins are known to be elevated and they do activate dendritic cells and result in T-cell activation. Now, whether that can be spelled out into actually some future drug therapy definitely remains to be seen. To date, there hasn't been any success in using heat shock types of agents or inhibitors, unfortunately. So, I think while this is of great interest, I'm not entirely sure that this will translate into any drug therapy in the future. Dr. Abdul Rafeh Naqash: And I totally connect with you there as a phase 1 trialist. I completely agree that we see a lot of translational data, more often than not, going into the phase 1 site because many of these targets are not actionable. Now, from a DNA repair standpoint, you did see that there was interference with DNA repair, as far as some of the analyses that you did, but I did not specifically see any markers for DNA damage that were assessed on the biopsies such as Gamma-H2AX, RAD 51, or Phospho-NBS. Was there a reason why that was not looked at? Dr. Thanh Dellinger: I think that we did look at that and there weren't really any significant results. We did put some of the data into the supplementary data. I think that in the end, our cohort was really too small to really make any meaningful data. But I absolutely agree with you looking at HSP and DNA repair is really important. And as I mentioned that most recently published paper does address that. Dr. Abdul Rafeh Naqash: Excellent! Do you think that there could be any confounders in this analysis that could have led to the upregulation of some of these pathways and may not necessarily have been the intraperitoneal chemotherapy? Could you think of some other reasons that this could have been a confounding factor? Or would it primarily be attributed to the intraperitoneal chemotherapy that you guys have looked at in this interesting paper? Dr. Thanh Dellinger: Yeah, it is a rather small cohort. So, I think that more data is required to potentially repeat this in the larger cohort. But what is interesting is that we did have paired analysis. So, we had matched peritoneal samples from the same patients looking before the HIPEC and after the HIPEC, which is very unique and hasn't really been done in the setting before. And while you couldn't necessarily repeat the same exact peritoneal tumor it was very close. And so, in the best setting, I think that we did have a good paired analysis. Dr. Abdul Rafeh Naqash: That was one of the very interesting aspects of this study that I very much appreciated, that you were able to get some of those paired biopsies and do the analyses on samples and look at all these markers. So, this was all excellent work and definitely intrigues the mind into what other ways one could use some of these findings to develop future combination-based approaches, whether it's the neoadjuvant or the adjuvant setting for patients with ovarian cancer. Are there any next steps as part of this project that you are excited about that you can share? Dr. Thanh Dellinger: Right! I'm definitely very excited about trying to build on this and essentially developing a much larger predictive study using hundreds of ovarian cancer HIPEC-treated tumors in collaboration with others. We have definitely developed a great community of HIPEC investigators who are very interested in developing somewhat of a predictive signature for ovarian cancer undergoing HIPEC. So, I'm very excited to hopefully be able to develop this consortium of HIPEC transcriptomic research. And so, I'm looking forward to collaborating with my co-investigators on that. Dr. Abdul Rafeh Naqash: It was definitely exciting to talk to you about your work. Now, I want to ask you about you as an investigator or as a researcher. How did you end up in this field? What was your background while you were pursuing science and medicine? How did you end up in this field and how are you mentoring the next generation? Dr. Thanh Dellinger: When I was a fellow at UCI, my mentor Robert Bristow introduced me to HIPEC and that has really stuck. As a GYN oncologist, it is hard to really do both chemo and be a good surgeon. And in many ways, I have really specialized in surgical oncology more than in medical oncology. And HIPEC is really a very nice blend of the two. It allows you to do clinical trials while still doing surgery and giving some chemotherapy. Really, it was for the introduction of my more recent mentor, Elena Rodriguez, who really introduced me to genomics and applying this to HIPEC samples that this all came about. And so, I think that there are a lot of opportunities for surgical oncologists who do not give chemo and may think that clinical research is not for them, but there are a lot of translational opportunities and clinical trial opportunities for those who don't give chemotherapy, but are surgical oncologists. Dr. Abdul Rafeh Naqash: Thank you so much. We are really excited for all the work that you're doing and will continue to do and hopefully, we'll see more of this evolve as time progresses. Dr. Thanh Dellinger: Thank you so much, Dr. Naqash. It was such a pleasure meeting you and talking to you. Dr. Abdul Rafeh Naqash: Same here. Thank you for listening to JCO Precision Oncology Conversations. To listen to more, visit asco.org/podcasts, or find them on Google Play Spotify and Apple podcasts. To stay up to date, be sure to follow and share JCO Precision Oncology content on Twitter. The Twitter handle is @JCOPO_ASCO. All JCO PO articles and series can be found at ascopubs.org/journals/PO. The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Guest Bio Dr. Thanh Dellinger, MD, is a gynecologic oncologist and physician-scientist who specializes in ovarian and uterine cancer. She is an expert in hyperthermic (HIPEC) and pressurized aerosolized intraperitoneal chemotherapy (PIPAC), and is the primary investigator of clinical and translational studies focusing on these therapies. She received her medical degree at University of California Irvine, where she also completed a gynecologic oncology fellowship. She is leading the first U.S. clinical trial in PIPAC (pressurized intraperitoneal aerosolized chemotherapy), a novel therapy using pressurized aerosolized chemotherapy for ovarian cancer. Her current research focuses on innovative therapies for ovarian cancer using intraoperative chemotherapy, and novel antibody and nanoparticle therapies.

The Teenage group of adventures continue their adventures, as they leave town to do some investigation. Be careful crossing bridges! Always look underneath just in case there is something under there! Does Buzz get killed? Deanna gets her first Critical and Katy Wicker Joins the cast!  Loaded Dice Rollers is a real play Pathfinder podcast and Pathfinder e2 Podcast. Like Critical Role, Glass Cannon, and Adventure Zone. We are Improv actors and hollywood actors, film director and television producers who grew up playing Dungeons and Dragons and other Role Playing Games.  Our love for RPG, D&D, Dnd, and Pathfinder inspires the miniatures, sets, and miniature terrains to bring our tabletop game nights to life.  We are a group of friends that are nerdy and we are the best nerds we can be to make sure life is good. Some would say, cool nerds!  I you like to watch Critical Role live, you'll love our edited version of our shows.  ale on iTunes, Google Play & Spotify.   Follow us! Facebook: https://www.facebook.com/gaming/loadeddicerollers Twitter: https://twitter.com/GmMacleods Instagram: https://www.instagram.com/gm_macleods/ Twitch: twitch.tv/loadeddicerollers

Welcome back to another episode of the Drive & Dish NBA Podcast, hosted by Kevin Rafuse (@rafusetolose) & Justin Cousart (@JustinContheAir). Kevin calls iso and goes solo this week, as he breaks down the first few games of the second round of the NBA playoffs. Kevin also discusses the outlook for the season for the team's eliminated in the first round, plus Jokic wins MVP, Rudy wins DPOY & Thibs wins COY. If that's not enough, we've also got some Who's Ballin Who's Fallin featuring some coaching changes. Thanks for bearing with our technical difficulties! Subscribe to the podcast on iTunes & leave us a review. Non-Apple users subscribe on Stitcher, Spreaker, Amazon Music, Google Play & Spotify. Watch the podcast on The Drive & Dish NBA channel on YouTube.

Join Shane Wilber for this week's NTL Now Podcast for a recap of NTL Basketball this week including the Towanda/NEB Girls showdown as well as analysis from Wellsboro/Canton & Troy/Towanda. Wrestling recaps include analysis on this past weekend's Quad Meet at Canton plus the Canton/Towanda & Athens/Wyalusing Duals this week. This week's pod includes sound bites from Wellsboro Boys BBall Coach Steve Adams, Canton Wrestling Coach Lyle Wesneski and Canton Wrestler Riley Parker. Listen live on ITunes, Google Play & Spotify. 

It's no secret that Mental Health has come to the forefront of conversation in the last few months now more than ever. With that being said we wanted to provide a few ways on how to prioritize your mental health in this season where stress is at an all-time high.. If you'd like to share feedback or just to say hi, Send a note to info@jonathanjonesspeaks.com⁣ ⁣⁣ Don't forget to follow us on Instagram,⁣⁣ ⁣⁣ Jonathan: ⁣⁣ https://www.Instagram.com/jonathanjonesspeaks⁣⁣⁣ ⁣⁣ Also, don't forget to check us out on YouTube @ Jonathan J Speaks⁣⁣ https://www.youtube.com/jonathanjonesspeaks⁣⁣⁣⁣ ⁣⁣ Very grateful that you are tuning in to this episode of the Speak Your Success Podcast! If you haven’t done so already, please take a moment to leave a quick rating and review of the show on Apple Podcast by clicking the link below. This will help us to continue to encourage like-minded high achievers with entrepreneurial insight and tangible application from my failures, scars, and successes to better serve you. ⁣⁣ ⁣⁣⁣ Apple⁣⁣: https://podcasts.apple.com/ao/podcast/speak-your-success/id1326991279 Google Play: Spotify⁣⁣ https://open.spotify.com/show/3h2UQceTTYvZAMs5dercTB --- Send in a voice message: https://anchor.fm/syspodcast1/message

Charles-Alexis, Antoine et Sébastien parlent de la première semaine du camp d’entraînement et discutent des forces en présence dans la centrale. Disponible sur: Apple Podcasts ↔️ Google Play ↔️ Spotify ↔️ L’article Passion MLB – S04 – EP20: Qui gagnera dans la Centrale? est apparu en premier sur RadioH2O.

Episode #31 Presented by the Bigger and Bradder Sports show! We hit the following topics: - Discuss the possible shortened season and re-aligned MLB divisions. - So much more! STAY SAFE!!! Tune in, like and subscribe!! Find us on iTunes, Google Play + Spotify, just search Yankee Chatter. We're also on Facebook, Instagram + Twitter!! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Episode #30 Presented by the Bigger and Bradder Sports show! We hit the following topics: - Sports are still on hiatus, what are we each doing to pass the time? - Joe DiMaggio + Ted Williams - 1998 Yankees vs. 1975 Reds STAY SAFE!!! Tune in, like and subscribe!! Find us on iTunes, Google Play + Spotify, just search Yankee Chatter. We're also on Facebook, Instagram + Twitter!! Also, subscribe to the Bigger and Bradder Sports Show! Help us get to 2,000 subscribers! There's a giveaway involved!! https://www.youtube.com/channel/UCKLrmuSmCu9AkkuV63W9sBA --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Episode #28LIVE podcast, with the Bigger and Bradder Sports show!We hit the following topics:- MLB along with other professional and collegiate sports organizations have suspended play for the time being due to the Coronavirus - how does this impact the Yankees??Tune in, like and subscribe!!Find us on iTunes, Google Play + Spotify, just search Yankee Chatter.We're also on Facebook, Instagram + Twitter!! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Episode #29LIVE podcast, with the Bigger and Bradder Sports show!We hit the following topics:- Sports are still on hiatus, what does this mean for baseball when it comes back?- How valid is it to call yourself a World Champion for a shortened season? - General thoughts and discussion on the coronavirusTune in, like and subscribe!!Find us on iTunes, Google Play + Spotify, just search Yankee Chatter.We're also on Facebook, Instagram + Twitter!!Also, subscribe to the Bigger and Bradder Sports Show! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Episode #27LIVE podcast, with the Bigger and Bradder Sports show!We hit the following topics:- Latest Yankees injuries (Stanton + Severino)- Hot Takes on Andujar, Clint Frazier, and rounding out the starting rotation.- Where does Andujar play more innings in 2020? Infield or OutfieldTune in, like and subscribe!!Find us on iTunes, Google Play + Spotify, just search Yankee Chatter.We're also on Facebook, Instagram + Twitter!!Also, subscribe to the Bigger and Bradder Sports Show!https://www.youtube.com/channel/UCKLrmuSmCu9AkkuV63W9sBA --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Episode #26LIVE podcast, with the Bigger and Bradder Sports show!We hit the following topics:- Astros cheating scandal updates - Astros Spring Training Press Conference (02.13.2020)- MLB Playoff re-structuringTune in, like and subscribe!!Find us on iTunes, Google Play + Spotify, just search Yankee Chatter.We're also on Facebook, Instagram + Twitter!! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Episode #25LIVE podcast, with the Bigger and Bradder Sports show!We hit the following topics:- Mookie Betts trade between the Dodgers and Red Sox and the current hurdles.- The Mets sale going awry, and Cohen backing out.- James Paxton injury + cutting him some slack- Spring Training starting NEXT WEEK!- The availability of Kris Bryant and Nolan ArenadoTune in, like and subscribe!!Find us on iTunes, Google Play + Spotify, just search Yankee Chatter.We're also on Facebook, Instagram + Twitter!! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

After a quick break, the guys are back with another episode of the Drive & Dish NBA podcast. Justin (@JustinContheAir) is off this week but Kevin (@rafusetolose) is joined by Chris Crawford (@ESPN580CC) from ESPN 580 Orlando to recap NBA media day. The guys take an overall look at the state of the league and discuss how this year there's a lack of bad teams compared to years past. Kevin talks his surprise that Josh Jackson is starting off the year in the G-League and what's gone wrong for him since Phoenix. Chris and Kevin debate the Warriors playoff chances after they confirm Klay Thompson will be out until the All-Star Break. Kevin asks Chris is James Harden's 1 legged 3 pointer is a good shot, and if Markelle Fultz shot is truly back. All that plus, Shaq vs. Dame rap beef, the Bucks are fined for saying they'll pay Giannis and Jimmy Butler waking up at 3:30 AM. Download and subscribe on iTunes, Sticher, Google Play & Spotify and watch the podcast on YouTube!(0:00-0:50) Intro(1:30-5:10) State of the league, lack of bad teams(5:10-8:45) Josh Jackson starting in the G-League(8:45-11:35) Klay Thompson confirmed out until the All-Star break(11:35-13:45) James Harden 1 legged 3 pointer talk(13:45-16:20) Paul George not playing until November(16:20-18:30) James Johnson not meeting Heat conditioning requirements, Jimmy Butler waking up at 3:30(18:30-23:15) Markelle Fultz shot video(23:15-25:40) Bucks fined by NBA for saying they'll give Giannis the Super Max(25:40-30:27) Shaq vs. Dame rap beef/Shaq MVP talkLearn more about your ad choices. Visit megaphone.fm/adchoices

THROUGH HELL AND BACK! The 11th Ultimate 30-Minute Motivational Speech Compilation is finally here! These are some of the best Motivational Videos that I have ever heard and that I continue to listen to to get motivated! ------------------------------ ►Subscribe for New Motivational Videos Every Week: http://bit.ly/MotivationVids If you enjoyed this video please Like, Comment and Subscribe for more! ►More of our Best Motivational Compilations: BEST EVER #6: http://bit.ly/2r0rM11 BEST EVER #7: http://bit.ly/2vhzWnX BEST EVER #8: http://bit.ly/2vPyr5h BEST EVER #9: http://bit.ly/2xRbH65 To get notified of new videos hit the bell beside the subscribe button! ▂▂▂▂▂▂▂▂▂▂▂▂▂ ►Thumbnail: Josh Mario John https://www.instagram.com/spizoiky/ ►Photographer: Lane Dorsey Follow him on Instagram: http://bit.ly/LaneDorsey http://lanedorsey.com/ ▂▂▂▂▂▂▂▂▂▂▂▂▂ Speakers: ►Les Brown https://lesbrown.com/ ►William Hollis: https://goo.gl/VQ5NGL http://thewilliamhollis.com ►Walter Bond Website: https://walterbond.com/ YouTube: https://www.youtube.com/user/WalterBo... Facebook: https://www.facebook.com/WalterBondMo... Instagram: https://www.instagram.com/walter_bond/ Twitter: https://twitter.com/walterbond LinkedIn: https://www.linkedin.com/in/walterbon... Book: https://walterbond.com/book-walter-bond/ ►Chris Traina YouTube: https://www.youtube.com/user/ctrain03 ►Billy Alsbrooks YouTube: https://www.youtube.com/channel/UCsWPqhHxzcLol3lNoimhZFw Get Billy Alsbrooks New Book Blessed and Unstoppable Now at: http://BlessedAndUnstoppable.com ►Eric Thomas YouTube: https://www.youtube.com/user/etthehip... Website: https://etinspires.com ►Chris Traina: http://bit.ly/ChrisTraina ▂▂▂▂▂▂▂▂▂▂▂▂▂ ►Connect with us on Social Media: Facebook: https://www.facebook.com/Motiversity/ Instagram: https://www.instagram.com/motiversity/ Twitter: https://twitter.com/motiversity_ Website: https://www.motiversity.com/ Spotify: https://goo.gl/uCEkJz Soundcloud: https://soundcloud.com/motiversity ▂▂▂▂▂▂▂▂▂▂▂▂▂ ►Creator - Video/Speech Used: 1. It's Possible - Motivation2Study https://www.youtube.com/watch?v=A5nsUjQFvok 2. Yes You Can - Motivation Archive https://www.youtube.com/watch?v=roiFtB8vPgo 3. Struggle makes you Stronger- Fearless Motivation https://www.youtube.com/watch?v=Wcf5b3mENJU 4. Winners Mindset - Motiversity https://www.youtube.com/watch?v=jj3EJ6nfBPU 5. Stand Up and Fight - Motiversity (1/2) https://www.youtube.com/watch?v=56_6CytNZ5E 6. Victory Is Mine - Motiversity https://www.youtube.com/watch?v=QXDvq_g6kHo 7. Truth Is the New Black - Billy Alsbrooks https://www.youtube.com/watch?v=yLcWcHCJrKc 8. Stand Up and Fight - Motiversity (2/2) https://www.youtube.com/watch?v=56_6CytNZ5E Video Sources: ►Fitness Serbia - Couple Fitness Motivation https://www.youtube.com/channel/UCk-u... ►“Cognitive Science and Artificial Intelligence (Bachelor) - Tilburg University” by TilburgUniversity , is a derivative work licensed under CC BY. https://www.youtube.com/watch?v=rEuyC... ► “Study at Reykjavik University ” by Háskólinn í Reykjavík - Reykjavik University, is a derivative work licensed under CC BY. https://www.youtube.com/watch?v=iZ1No... ► “Veränderung leben. Der Macromedia-Imagefilm ” by Hochschule Macromedia, University of Applied Sciences - https://www.youtube.com/watch?v=siNy7... Max description length reached. For all video sources please see the individual videos used. ▂▂▂▂▂▂▂▂▂▂▂▂▂ MUSIC: ►Victory Is Mine - Chris Traina and Motiversity Download or Stream it on iTunes, Spotify or Google Play: Spotify: https://goo.gl/uCEkJz Apple Music: https://goo.gl/Wt3M3t GooglePlay: http://bit.ly/2Fy9lcB Soundcloud: https://goo.gl/mh4Rrz AmazonMP3: https://goo.gl/AUEt2e iTunes: https://goo.gl/Wt3M3t ►Struggle makes you Stronger - Team Fearless Music & Speech by Fearless Motivation http://www.fearlessmotivation.com/ Download or Stream it on iTunes, Spotify or Google Play: iTunes: https://goo.gl/T5gm5W GooglePlay: https://goo.gl/NciJJS Spotify: https://goo.gl/tlEU5T AmazonMP3: http://amzn.to/2hJlkdA ►Really Slow Motion - Grandiose ►Really Slow Motion - A First Star Buy their music: Amazon : http://amzn.to/1lTltY5 iTunes: http://bit.ly/1ee3l8K Spotify: http://bit.ly/1r3lPvN Bandcamp: http://bit.ly/1DqtZSo ►Audiomachine - Impera http://audiomachine.com/ ▂▂▂▂▂▂▂▂▂▂▂▂▂ ►Fair Use Disclaimer: Our purpose, when making motivational videos, is to make quality educational motivational videos and share these with our viewers. 1)This video has no negative impact on the original works (It would actually be positive for them) 2)This video is also used for teaching purposes. 3)It is transformative in nature. 4)I ONLY used bits and pieces of videos to get the point across where necessary. If you are the legal content owner of any videos here and would like them removed please message me at joel@motiversity.com ▂▂▂▂▂▂▂▂▂▂▂▂▂ Help us caption & translate this video! https://amara.org/v/fGrU/

From the corporate world within the beginning days of Microsoft to Tarot Cards and Yoga.    David Flenniken shares his story how he managed his spiritual life living in the corporate world and what lead him to create his own Tarot Cards and to teaching yoga.    Throughout this Episode you will learn:  the importance of doing vs talking at events  how to honor your routine the key to showing up fully  understanding your emotions  the art of listening to other and self how to read the consciences of different cultures  how to perform with distractions vs peace and quiet  addressing anxiety is a consciences skill  focus concentration is getting away what you think you need to work on  how sometimes we communicate from past wounds  Mercury retrograde and the effects within communication    David explains Tarot Cards and gives a free reading for Anna Willard. Listen in and see what is in store for the future and what Anna will be working on for you!    WATCH EPISODE HERE    For more information about David Flenniken follow the links below Tarot, Yoga & Web-software Admin of  http://MahalasAstrology.com & Founder of  http://AmorStyleAstrology.com & http://AmorStyleTarot.com & http://AmorStyleHealing.com & http://AmorStyleYoga.com   SAVE THE DATE JUNE 22-23rd FOR WOMEN OF IRON STRENGTH RETREAT Join Anna Willard and Anne Casstevens as they will be hosting this retreat as they will give you strategies for gaining PR's in your pistol squat, pull-up, and press.   For more details about the workshop Click Here     For more inspiration check out Anna Willard's book Spark Your Youth: A 21-Day Fitspirational to give you hope and the power to believe.   Thank you for joining! Anna Willard is excited to take this journey with you! If you enjoyed what you heard, subscribe to receive future episodes and share your love with a great review and 5 Stars.   To train with Anna Willard with Kettlebells head to www.annawillard.com Let's Get Social Instagram Facebook LinkedIn YouTube   You can also listen here:  Stitcher  Google Play Spotify  

  THIS EPISODE YOU DON'T WANT TO MISS!!! Anna Willard jumps in with how using the phrase of "my story" can cause more harm than healing.  She shares the importance of understanding the interconnection of our stories and how stories are to unite each other.    When we hold onto the fact of "my story" we negate this connection and the invitation for all of us to heal. She shares the importance of being open to the healing process and allow others to heal along the journey.    This is the strength and art of letting go and to become open to a deeper strength to move through us to heal in ways we never thought possible.    SAVE THE DATE JUNE 22-23rd FOR WOMEN OF IRON STRENGTH RETREAT Join Anna Willard and Anne Casstevens as they will be hosting this retreat as they will give you strategies for gaining PR's in your pistol squat, pull-up, and press.   For more details about the workshop Click Here     For more inspiration check out Anna Willard's book Spark Your Youth: A 21-Day Fitspirational to give you hope and the power to believe.   Thank you for joining! Anna Willard is excited to take this journey with you! If you enjoyed what you heard, subscribe to receive future episodes and share your love with a great review and 5 Stars.   To train with Anna Willard with Kettlebells head to www.annawillard.com Let's Get Social Instagram Facebook LinkedIn YouTube   Stitcher  Google Play Spotify    

Street Wannabes interviewed Tamim Alnuweiri of Rose Gold Presents and Alt Citizen. We talked to her about booking shows, managing Gnarcissists & Rose Cologne, running Alt Citizen, NYC venues, Issue 7 of Alt Citizen, Surfbort and much more. Recorded 11/10, available on iTunes, Google Play & Spotify.Gnarcissists have a new 7" record "EP" out now! Next Show 12/15 at Elsewhere with The Black Lips. Help out Matti of Gnarcissists with his ACL surgery fund ( Paypal: ORRMATS@gmail.com Venmo: mattorr3)www.facebook.com/rosegoldpresents www.instagram.com/rosegoldpresents www.altcitizen.com www.facebook.com/altcitizen www.instagram.com/altcitizen www.gnarcissists.bandcamp.com/album/ep www.facebook.com/gnarcissists www.instagram.com/gnarcissists www.instagram.com/rosecologne www.streetwannabes.com

Top 7s are back!!!! Welcome to the new and improved LUCKY 7's where we bring you the top 7 in each catagory! Today we kick it back off with DARK EXPERIMENTS!!! Some weird shit has happened in history and humanity loves to torture one another so lets take a deeper look into some of the atrocities that have taken place!  Let us know what you thought & what you suspected would be #1 ...'5 Coven Points' if you guessed correctly ;)   NOW on iTunes, Google Play & Spotify.....and YouTube lol   Submit your (ANYTHING) HORROR to WitchesHillRadio@Gmail.com for a chance to be featured on an episode! (Please make sure we can access the content provided in the links!)   Follow us at    Twitter.com/Witches_Hill Facebook.com/groups/witcheshillhorrortalkshow  

With over 25 episodes of the weekly podcast plus all of the Yo MTV Raps Experience Specials, we realized we haven't shared the 2BlindMics origin story. Just how did the Hip Hop Broadcasting Legend Doctor Dre meet up with the Audio Advocate now known as Super Hero Sensei? That and more in our season finale. We won't be gone for long but make sure you subscribe so you know when we're back! Apple Podcast, Google Play Spotify, Stitcher Tune In Radio www.2BlindMics.com @2BlindMics on Twitter, Facebook & IG *** Apple Podcast: http://bit.ly/2BlindMics Google Play: http://bit.ly/2BlindMics-GPlay Holla Back! Give your opinion on an episode, the show or offer some topics! Call the 2BlindMics Hotline: 1 (516) 778-7933 Alternatively, send an email or record a voice message using your smart phone's voice recorder and send to 2blindmics@gmail.com.

2nd part of our interview with the wonderful Stephanie Davies. In this chat we talk about her brief venture into dance music, her work with Gran Cassa (including marrying the guitarist), DJ Stubble, the birth of Stephanie Davies & The Super Dynamics and her other current projects including the incredible vocal talents of Atlantic and her teaming up with my wife as the backing singers for Paul Cox’s tribute to the great Joe Cocker.   There is also a very interesting insight into what has become a staple of popular television. She finishes by expanding on a story she originally wrote for the CMV Action web-site (see link below)   www.cmvaction.org.uk    www.cmvaction.org.uk/our-stories/gabriel (for Steph’s original story she wrote)     Link for Atlantic Facebook page where you can make enquiries about bookings as well as see where public gigs are: https://www.facebook.com/teamatlanticband/    Link for Stephanie Davies & The Super Dynamics Facebook Page: https://www.facebook.com/Stephanie-Davies-The-Super-Dynamics-138748666173682/    Link to buy their new album on iTunes (also available to stream on Google Play & Spotify): https://itunes.apple.com/gb/album/find-a-new-way/1355900594 

Remember the song that Arlene sang to Gwen back in Chapter 6 and again in Chapter 9? We know at least some of you do, because you wrote in to tell us how much you loved it, and to ask whether it was available as a standalone track. Well...it is now! We re-recorded it with a new arrangement and live instruments. Head over to onceandfuturenerd.bandcamp.com to purchase it for $1 (or more if you'd like to be very kind. Patreon subscribers, check your Patreon feed for a coupon code to save 50¢.) And for today's bonus content, we talked to the talented folks involved for insight into making the song. Keep reading for full credits and attributions. "The Singing Sister" Copyright © 2015 by Gibian, Glass & Madera Lyrics by Zach Glass & Christian T. Madera, based on a traditional folk song Music by Anya Gibian This version arranged, orchestrated, and produced by Tom Lee. Recorded and Edited by Justin Tricarico at Studio 302, Queens College, Queens, NY. Performed by: Anya Gibian - Vocals Emily P. Dana - Harp, Violin, Viola Simona Donova - Flute Zach Glass - Trumpet Tom Lee - Percussion programming Kelsey Sheldon - Cello Mixed by Chris Montalbo of The Last Alliance. Executive Produced by Zach Glass & Christian T. Madera The Making-Of Featurette: This episode is heavily inspired by Song Exploder, which we highly recommend. Music used: "Cruel Sister" by Pentangle (Amazon | iTunes | Google Play | Spotify) Main Title Theme from HOUSE OF CARDS by Jeff Beal (Amazon | iTunes | Google Play | Spotify)